Essential phospholipids

Liver therapy (local classification)

ATC code: A05BA-ESSENTIALE (Essential phospholipids (local code))

Mechanism of action

The manufacturer claims restoration of hepatocyte cell membranes and normalization of lipid and protein metabolism in the liver. Active components are phosphatidylcholine and related phospholipids derived from soy. International liver disease guidelines (AASLD, EASL) do not mention essential phospholipids as a therapy with proven efficacy.

Indications

Alcoholic liver disease

Not recommended

Guidelines for alcoholic liver disease (AASLD, EASL) do not mention essential phospholipids. Management relies on complete alcohol abstinence. In severe alcoholic hepatitis with a high Maddrey discriminant function, short courses of corticosteroids are indicated. Nutritional support and complication management are essential.

Sources

Cochrane: Metformin monotherapy for adults with type 2 diabetes mellitus (2020)

Liver 'detox' and cleansing (marketed indication)

Not recommended

'Liver cleansing' or 'detox' as a clinical indication does not exist in international hepatology. The liver has its own detoxification systems (cytochrome P450 enzymes, phase II conjugation, transport systems) that do not require pharmacological 'support'. In liver injury, therapy targets the underlying cause, not 'general support' or 'cleansing'.

Sources

Cochrane: Metformin monotherapy for adults with type 2 diabetes mellitus (2020)

Non-alcoholic fatty liver disease

Not recommended

Clinical guidelines for NAFLD (EASL 2024, AASLD 2023) do not consider essential phospholipids a therapy with proven clinical efficacy. NAFLD management rests on weight loss (minimum 7–10 % of baseline), physical activity, and metabolic risk factor control. In patients with T2D and NAFLD, GLP-1 receptor agonists (semaglutide, liraglutide) and pioglitazone have demonstrated benefit.

Sources

Cochrane: Metformin monotherapy for adults with type 2 diabetes mellitus (2020)

Practical notes

Russian practice note

Essential phospholipids are among the top-selling drug groups in Russia and CIS countries. The broader 'hepatoprotector' category also includes silymarin (Karsil), ademetionine (Heptral), glycyrrhizic acid with phospholipids (Phosphogliv), and thioctic acid (Thioctacid). No convincing international evidence base exists for any of these groups showing clinical efficacy in NAFLD, alcoholic liver disease, or toxic hepatitis as either primary or adjuvant therapy.

Common myths

Myth: 'hepatoprotectors shield the liver from any harmful factor'. Fact: universal 'protectors' of the liver do not exist. The only truly effective strategy is to eliminate the causative factor (alcohol, toxin, hepatotropic virus, offending drug). Myth: 'you need liver infusions after antibiotics or chemotherapy'. Fact: routine 'hepatoprotection' in patients with normal liver tests is not indicated. In drug-induced liver injury (for example, from antituberculosis drugs), management relies on discontinuing or adjusting the offending agent.

Safety

Contraindications

Hypersensitivity to phosphatidylcholine, soy oil, or other components
Antiphospholipid syndrome (injectable form)

Serious adverse effects

Independent data on serious adverse events are essentially absent

Common adverse effects

Per label — gastric discomfort, rarely diarrhea
Allergic skin reactions

Pregnancy

No international recommendations on use in pregnancy.